Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 2,082 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Open Label Extension Study Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients

NCT02666430
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Mylan's insulin glargine, Lantus®
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
18 Years to 66 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
39
States / cities
Fresno, California • Greenbrae, California • La Jolla, California + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 28, 2026, 5:07 PM EDT
Completed Phase 3 Interventional Results available

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

NCT01665144
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis
Interventions
BAF312, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
1,651 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
52
States / cities
Phoenix, Arizona • Berkeley, California • Los Angeles, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Oct 28, 2026, 5:07 PM EDT
Completed Phase 4 Interventional Results available

EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension

NCT03497689
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Intravenous/Subcutaneous Treprostinil; Oral Treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
11
States / cities
Fresno, California • Torrance, California • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Oct 28, 2026, 5:07 PM EDT
Completed Phase 2 Interventional Results available

Rimegepant in Moderate Plaque-type Psoriasis

NCT04629950
View directory record Official record
Conditions
Psoriasis
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 28, 2026, 5:07 PM EDT
Terminated Phase 2 Interventional Results available

Study of Lademirsen (SAR339375) in Patients With Alport Syndrome

NCT02855268
View directory record Official record
Conditions
Alport Syndrome
Interventions
lademirsen (SAR339375), Placebo
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
5
States / cities
Los Angeles, California • Minneapolis, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 28, 2026, 5:07 PM EDT
Terminated Phase 2 Interventional Results available

Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021

NCT02342548
View directory record Official record
Conditions
Huntington's Disease
Interventions
20 mg BID of PF-02545920
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 66 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Irvine, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 28, 2026, 5:07 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Daratumumab

NCT05438043
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab, Carfilzomib, Dexamethasone, Lenalidomide, Pomalidomide
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
7
States / cities
Miami, Florida • Atlanta, Georgia • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 28, 2026, 5:07 PM EDT
Completed Phase 2 Interventional Results available

Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003

NCT03847974
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
LIB003
Drug
Lead sponsor
LIB Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 28, 2026, 5:07 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

NCT01815736
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
E/C/F/TAF, E/C/F/TDF, EFV/FTC/TDF, RTV, ATV, FTC/TDF, COBI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
91
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 28, 2026, 5:07 PM EDT
Not listed Phase 2 Interventional

Safety, Tolerability, and Exploratory Efficacy of Adjunctive EQU-001 for Seizures in Adults With Epilepsy

NCT05063877
View directory record Official record
Conditions
Epilepsy
Interventions
Placebo, EQU-001
Drug
Lead sponsor
Equilibre Biopharmaceuticals B.V.
Industry
Eligibility
18 Years to 60 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
Boise, Idaho • Bethesda, Maryland • Hackensack, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Oct 28, 2026, 5:07 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease

NCT00566501
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Donepezil
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
45 Years to 91 Years
Enrollment
915 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Oct 28, 2026, 5:07 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

NCT01464307
View directory record Official record
Conditions
Post-stroke Spasticity of the Lower Limb
Interventions
IncobotulinumtoxinA (400 Units), Placebo Comparator
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 80 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
12
States / cities
Downey, California • Long Beach, California • Fairfield, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 28, 2026, 5:07 PM EDT
Completed Phase 3 Interventional

A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine

NCT04686136
View directory record Official record
Conditions
Episodic Migraine, Chronic Migraine
Interventions
Atogepant 60 mg
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
42
States / cities
Phoenix, Arizona • Fresno, California • Los Alamitos, California + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 28, 2026, 5:07 PM EDT
Completed Phase 3 Interventional

Study to Evaluate the Efficacy of Modafinil Treatment in Patients With Attention Deficit Hyperactivity Disorder (ADHD) Who Are Responders to Modafinil Treatment

NCT00343811
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Modafinil
Drug
Lead sponsor
Cephalon
Industry
Eligibility
6 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
23
States / cities
Little Rock, Arkansas • Irvine, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 28, 2026, 5:07 PM EDT
Completed Phase 4 Interventional Results available

SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"

NCT04033367
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
8
States / cities
North Little Rock, Arkansas • Redwood City, California • Rolling Hills Estates, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 28, 2026, 5:07 PM EDT
Enrolling by invitation Phase 3 Interventional

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

NCT05645536
View directory record Official record
Conditions
Breast Cancer
Interventions
TOL2506, Tamoxifen, Letrozole tablets, Anastrozole Tablets, Exemestane Tablets
Drug
Lead sponsor
Tolmar Inc.
Industry
Eligibility
18 Years to 51 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
17
States / cities
Greenbrae, California • Fort Lauderdale, Florida • Lexington, Kentucky + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 28, 2026, 5:07 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02417064
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
37
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Garden Grove, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 28, 2026, 5:07 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects

NCT02135692
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab, SOC
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
16
States / cities
Newport Beach, California • Riverside, California • Rolling Hills Estates, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 28, 2026, 5:07 PM EDT
Completed Phase 3 Interventional

Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial

NCT01593228
View directory record Official record
Conditions
Solid Tumors
Interventions
Iniparib (SAR240550/BSI-201), Carboplatin, Doxorubicin HCL liposome injection, Gemcitabine, Irinotecan, Paclitaxel, Topotecan
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
29
States / cities
Birmingham, Alabama • Santa Maria, California • Vallejo, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Oct 28, 2026, 5:07 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma

NCT02371746
View directory record Official record
Conditions
Glaucoma and Ocular Hypertension
Interventions
ENV515-3 Travoprost XR, ENV515-1 Travoprost XR, ENV515-3-2 Travoprost XR
Drug
Lead sponsor
Envisia Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
14
States / cities
Chandler, Arizona • Garden Grove, California • Inglewood, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Oct 28, 2026, 5:07 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)

NCT05776069
View directory record Official record
Conditions
Von Willebrand Diseases
Interventions
VGA039, Placebo
Drug · Other
Lead sponsor
Vega Therapeutics, Inc
Industry
Eligibility
12 Years to 60 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
10
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 28, 2026, 5:07 PM EDT
Active, not recruiting Phase 2 Interventional

A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)

NCT06924970
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Tebapivat, Tebapivat Matched Placebo
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
16 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Farmington, Connecticut • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 28, 2026, 5:07 PM EDT
Completed Phase 3 Interventional

A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

NCT04901195
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
658 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 28, 2026, 5:07 PM EDT
Completed Phase 3 Interventional Results available

Dasotraline Pediatric Extension Study

NCT02457819
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Dasotraline
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
36
States / cities
Dothan, Alabama • Culver City, California • Wildomar, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 28, 2026, 5:07 PM EDT